A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir

Hepatology Research

Volumn 38, Issue 8, 2008, Pages 842-846

  Fukushima, Koji ^a   Ueno, Yoshiyuki ^a   Inoue, Jun ^a   Wakui, Yuta ^a   Obara, Noriyuki ^a   Kimura, Osamu ^a   Kido, Osamu ^a   Nakagome, Yu ^a   Kakazu, Eiji ^a   Matsuda, Yasunori ^a   Kogure, Takayuki ^a   Kondo, Yasuteru ^a   Nagasaki, Futoshi ^a   Yamagiwa, Yoko ^a   Ashino, Yugo ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Co infection; Entecavir; Hepatitis B virus; HIV

Indexed keywords

ATAZANAVIR; EMTRICITABINE; ENTECAVIR; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; DELETION MUTANT; DRUG EFFICACY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 47649130103     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00332.x     Document Type: Article

References (22)

1. Lindegren ML, Kobrynski L, Rasmussen SA et al. Applying public health strategies to primary immunodeficiency diseases: A potential approach to genetic disorders. MMWR Recomm Rep 2004; 53: 1-29.
2. Soriano V, Miro JM, Garcia-Samaniego J et al. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations. J Viral Hepat 2004; 11: 2-17.
3. FDA Notifications. Entecavir revision made by FDA and BMS. AIDS Alert 2007; 22: 43.
4. Revill PA, Littlejohn M, Ayres A et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. Aids 2007; 21: 1701-10.
5. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
6. Akuta N, Suzuki F, Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38: 315-21.
7. Innaimo SF, Seifer M, Bisacchi GS et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 1444-8.
8. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006; 44: S90-4.
9. Rathbun RC, Lockhart SM, Stephens JR. Current HIV treatment guidelines - an overview. Curr Pharm Des 2006; 12: 1045-63.
10. Orito E, Ichida T, Sakugawa H et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-4.
11. Sugauchi F, Orito E, Ohno T et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 2006; 36: 107-14.
12. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-34.
13. Shibayama T, Masuda G, Ajisawa A et al. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. J Med Virol 2005; 76: 24-32.
14. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-21.
15. Gunther S, Piwon N, Jung A et al. Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene. Virology 2000; 273: 286-99.
16. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
17. Marschenz S, Endres AS, Brinckmann A et al. Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology 2006; 131: 765-80.
18. Gatanaga H, Ibe S, Matsuda M et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007; 75: 75-82.
19. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
20. Shire NJ, Sherman KE. Management of HBV/HIV-coinfected patients. Semin Liver Dis 2005; 25 (Suppl. 1): 48-57.
21. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39: 129-32.
22. Takahashi M, Nishizawa T, Gotanda Y et al. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol 2004; 11: 392-8.